Despite these challenges, the discovery of KRAS inhibitors has ushered in a time of cautious optimism that the upward rate of pancreatic cancer deaths and the incremental steps in improvements to the 5-year survival rate of PDAC may soon be in our past. This evidence concerns the gene KRAS and familial pancreatic carcinoma.